# Co-investor referral confidentiality checklist | SourceX

Canonical: https://refer.sourcex.si/guides/how-to-keep-a-co-investor-s-confidentiality-promise-intact
Last updated: 2026-11-05

Treat whatever a co-investor told you about a company as information still bound by the co-investor's promise to that company, not as yours to pass on. Before a SourceX introduction, tag each fact by where you learned it. Public facts, and what the CEO tells you directly, can travel once the CEO agrees to be introduced. Anything that reached you through the co-investor, its board seat or its diligence stays behind unless the co-investor and the CEO both say otherwise.

Co-investors talk. A syndicate call, an observer's aside after a board meeting, a forwarded deck: a VC ecosystem lead hears plenty about companies their own fund has never been given. The checklist below sorts that knowledge before any of it lands in an introduction.

## Three promises sit on one introduction

A data introduction between funds touches three separate confidentiality promises, plus one permission that is not a promise at all.

| Promise | Made by, to whom | Where it is usually written | What a careless referral breaks |
|---|---|---|---|
| Confidentiality to the company | The co-investor, to the company | A confidential disclosure agreement, investor rights terms, a side letter | Using the company's non-public facts for a purpose they were not shared for |
| Discretion between investors | The co-investor and you, to each other | A syndicate email, a deal-sharing understanding, sometimes nothing written | Building your own ask on what the co-investor said in confidence |
| Confidentiality under the partner agreement | You and SourceX, to each other | The SourceX Channel Partner Agreement, section 4 | Relaying SourceX's non-public updates to the co-investor or the company |
| The CEO's permission (a gate, not a promise) | The CEO, to whoever introduces | A dated written yes | Introducing a company whose CEO never agreed |

**The co-investor's promise follows the information.** The NVCA's model confidential disclosure agreement for life science investors confines a receiving investor's use of company information to internal evaluation of a proposed transaction, and lets the investor share it with its own employees and representatives, including co-investors that already have their own agreement with the company (paraphrase). In that model, a fellow investor can hear the information only inside the frame it was given for. Evaluating a data licensing introduction is a different use. Your fund's documents may say something stricter or looser, so read them; the [use restriction guide](/guides/confidentiality-clause-use-restriction) walks through how such clauses are built.

**Your own promise to SourceX runs both ways.** The partner agreement defines confidential information to include introduction records, buyer identities, requirements and pricing (1.6). Each side may use the other's confidential information only for the referral relationship (4.1) and share it only with employees, professional advisers and service providers who need it and carry equally protective duties (4.2). A co-investor is not on that list. The agreement also gives a partner no authority to share a company's inventory, records, raw data or personal information (4.2), forbids disclosing non-public deal details without written authorization (4.5), and keeps these duties for three years after it ends (5.3), longer for trade secrets. If your fund signed a separate NDA with SourceX, it continues within its own scope (7.8).

**The CEO's permission comes before everything.** SourceX's screening guidance says introductions made without the decision maker's knowledge are usually not a fit. No amount of careful redaction makes up for a CEO who never agreed to be introduced.

## Trace each fact back to where you learned it

Origin decides travel. Before drafting anything, write each fact you would use next to one of four origins:

1. **Public.** The company's website, its own announcements, a public filing.
2. **The CEO, to you.** Said directly, in a meeting or message you were part of.
3. **The co-investor, in conversation.** A call, a dinner, a syndicate thread.
4. **Documents you hold through someone's rights.** Board packs, information-rights reports, a data room, a diligence memo.

Facts from origins 1 and 2 can go to SourceX once the CEO agrees to be introduced. Facts from origins 3 and 4 cannot, unless the co-investor agrees and the CEO restates them to you herself. The partner agreement's own exclusions are a useful model of what usually falls outside a confidentiality duty: information that is public without a breach, known before without restriction, developed independently or received lawfully from someone with no duty (4.3). The co-investor's documents will carry their own list, and theirs is the one that binds the co-investor.

## The permission and disclosure boundary checklist

Twelve facts a fund typically holds about a company it co-invests in, each with its usual origin, whether it may reach SourceX, whose yes comes first, and the promise at risk if it slips.

| # | Fact | Usual origin | May it reach SourceX? | Whose yes first | Promise at risk if it slips |
|---|---|---|---|---|---|
| 1 | Company legal name and website | Public | Yes, after the CEO agrees to be introduced | The CEO | None, once the CEO agreed |
| 2 | The CEO's name and email | Public, or from the CEO | Yes, after the CEO's yes | The CEO | Discretion between investors, if the co-investor supplied the address |
| 3 | That an introduction is under way | Your own action | Only among you, the CEO and SourceX | The CEO | Partner agreement 4.5 (non-public deal details) |
| 4 | Full-time headcount at its peak | The CEO, or public | As the CEO states it | The CEO | Company confidentiality, if taken from a board pack |
| 5 | Years of records, systems and record types | The CEO | As metadata, in the CEO's words | The CEO | Company confidentiality, if taken from diligence |
| 6 | A dated event, such as a system retirement | The CEO or a public announcement | If the CEO raises it | The CEO | Company confidentiality, if learned through information rights |
| 7 | Board figures: revenue, churn, pipeline | The co-investor's board seat | Never | Not yours to clear | Company confidentiality |
| 8 | The co-investor's diligence memo or data room | The co-investor | Never | Not yours to clear | Company confidentiality and discretion between investors |
| 9 | The co-investor's view of the company or CEO | The co-investor | Never | Not yours to clear | Discretion between investors |
| 10 | Who holds shares, and on what terms | The cap table | Not needed; leave it out | The co-investor | Discretion between investors |
| 11 | SourceX's stage updates on your referral | SourceX | Stays inside your fund | SourceX, in writing | Partner agreement 4.1 and 4.6 |
| 12 | Any reward estimate | Your partner dashboard | Stays inside your fund; never to the company | Nobody | Partner agreement 4.6; it also exposes the payout |

Three of the rows deserve a line each. Row 5 is metadata, not records: what kind, roughly how much, over how many years, in which system, owned by whom. Files, samples and logins never travel, whoever offers them. Row 11 exists because terms section 7 already keeps other partners' records from you, and the partner agreement keeps SourceX's updates inside your firm and the advisers bound to it. Row 12 matters twice over: the partner agreement forbids telling a company that an estimate or interest assures a purchase or a reward (4.6), and the terms call portal estimates projections, not promises.

**Method.** The twelve facts are the ones a co-investing fund commonly holds; each was tagged by origin and checked on 2026-10-27 against SourceX's partner agreement (sections 1.6, 4, 5.3 and 7.8), the program terms (sections 7 to 9), the screening guidance and the NVCA model agreement as excerpted. The checklist cannot read your own documents. A side letter or information-rights clause can be stricter or looser, and that document governs. For the professional rules that bind accountants, lawyers and advisers when they mention a client's name, see [what to share under a referral confidentiality clause](/resources/referral-agreement-confidentiality-clause).

## One introducer whose standing does not lean on the co-investor's file

The person who introduces should be someone whose own relationship with the CEO lets them ask without quoting anything learned in confidence. If your fund's only warm route to the CEO runs through the co-investor, then the co-investor asks or declines, and a decline ends it.

Ask the co-investor first, in plain words: "May I raise a SourceX introduction with your CEO myself, using only public facts and the program's fit tests, and mentioning nothing you have told me?" A yes in writing covers the discretion between you. It does not release the co-investor's duty to the company, and it does not replace the CEO's own yes. One sender, one message, public facts only: the CEO hears the program described, decides, and tells you about her company in her own words if she wants to go ahead. The [duplicate-claim checklist](/guides/how-to-prevent-duplicate-claims-before-they-reach-sourcex) helps you confirm nobody else has already introduced her.

## Progress reports and rewards inside the confidentiality lines

**Progress.** SourceX gives a partner what it reasonably needs to follow its own referral and reward, as generic stages or reference codes (4.6). Those updates stay inside your fund. The co-investor hears how things are going from the CEO, if the CEO chooses to tell her investors, never from you. Agree on that before the first message so nobody feels shut out later.

**Rewards.** One partner is credited per company. The reward is the greater of $50,000 plus 5% and 15% of Actual Supplier Payout, with no cap, paid separately by SourceX and never deducted from the company's compensation. Illustrative only: an Actual Supplier Payout of $400,000 would mean a $70,000 reward to the credited partner and nothing to the co-investor. If the co-investor helped and your firms want to recognize it, that is an arrangement between the funds, outside the program, and both firms' rules apply. Keep figures out of it with the company: because the reward tracks the payout, quoting one discloses the other, and the payout is a non-public deal detail.

## A board observer's aside and an associate's draft (Illustrative)

Illustrative: Fund A and Fund B co-invested in a 190-person medical equipment service company that keeps fourteen years of service tickets and repair logs it created itself. Fund B holds a board observer seat. On a syndicate call, Fund B's partner mentions that the latest board pack plans to retire the company's field service system next spring. A Fund A associate drafts a note to SourceX the same afternoon.

| Line in the first draft | Origin | Checklist verdict | What replaced it |
|---|---|---|---|
| "Fourteen years of service and repair records" | Fund B, from the board pack | Row 5 via origin 4: stays behind | Nothing, until the CEO described the records herself |
| "Retiring its field service system next spring" | Fund B, from the board pack | Row 6 via origin 4: stays behind | The CEO raised the retirement on her own call with Fund A |
| The CEO's direct email address | Fund B's syndicate thread | Row 2: discretion between investors | The card the CEO gave a Fund A partner at an industry event |
| "Revenue has doubled since the round" | Fund B, from board figures | Row 7: never | Deleted |

What happened next: Fund A asked Fund B first. Fund B agreed that Fund A could approach the CEO, provided nothing from the board pack was mentioned. The Fund A partner who knew the CEO wrote to her with public facts and the fit tests only. She said yes in writing and, on the call that followed, described the record history and the planned system retirement herself. With her agreement, those two facts went into the introduction as her words. Fund B learned that a conversation had started when the CEO told her board.

## Limits of a fact-by-fact test

- **Your documents govern, not a model.** The NVCA form is a template. A co-investor's actual agreement, and your own fund's side letters, may draw the lines elsewhere.
- **Origins blur.** A fact the CEO told you may also sit in the board pack. When unsure, ask the CEO to state it in writing and quote that.
- **The CEO cannot release everything.** She can clear the company's facts, not the co-investor's own confidences, such as its opinion of the company.
- **The company's own duties are a separate question.** Whether the company can license its records without breaking promises it made to its own customers or staff is part of SourceX's screening and rights review, not something any investor settles.
- **Shared tools leak.** Syndicate CRMs and shared notes can carry confidential facts into a draft without anyone noticing. Draft introductions outside them.
- **A clean introduction promises nothing.** Requirements vary with SourceX's current data needs and are checked in review; a confidentiality-perfect introduction can still end without a license.

## Next step

> **Refer a company. No cap on rewards.** Default reward on a company's first qualifying transaction: the greater of $50,000 plus 5% and 15% of Actual Supplier Payout, with no cap; further qualifying transactions first agreed within 12 months of the first Closing pay 15%. Eligibility and payment conditions apply, including the USD 100,000 Minimum Transaction, and a signed Schedule A or addendum can differ. A lead, meeting or signature alone does not trigger payment.

Run the twelve rows over your draft, ask the co-investor before you lean on anything it told you, and let the CEO's own words carry the facts; then [register as a partner](/register), test the company against [who qualifies](/who-qualifies) and read the confidentiality and attribution sections of the [program terms](/terms). The main site's comparison of [license confidentiality and training data disclosure](https://sourcex.si/ai-data/licensing/data-license-confidentiality-vs-transparency) covers what stays confidential once a license is signed, and the [overview for venture platform teams](/for/venture-platform-teams) sets out the fund-side program.

Keeping a co-investor's confidence is a referral question; judging SourceX as a possible investment is a different one, and readers weighing it can request materials through the [SourceX investor overview](https://sourcex.si/investors).

This article is for information only and is not an offer to sell or a solicitation of an offer to buy securities. Any offering by SourceX is made only to verified accredited investors through its offering documents.

## Sources

- https://refer.sourcex.si/terms
- https://sourcex.si/documents/partner/SourceX_Channel_Partner_Agreement_Sample.pdf
- https://refer.sourcex.si/who-qualifies
- https://nvca.org/wp-content/uploads/2019/06/NVCA-Model-Document-Life-Science-Confidential-Disclosure-Agreement.doc
- https://sourcex.si/investors
